Skip to Content

Ayala Pharmaceuticals Inc Ordinary Shares ADXS

Morningstar Rating
$0.30 +0.03 (12.38%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADXS is trading at a 717% premium.
Price
$0.26
Fair Value
$5.48
Uncertainty
Extreme
1-Star Price
$89.56
5-Star Price
$7.42
Economic Moat
Jjcrg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADXS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.26
Day Range
$0.270.30
52-Week Range
$0.141.95
Bid/Ask
$0.27 / $0.30
Market Cap
$12.57 Mil
Volume/Avg
1,743 / 9,771

Key Statistics

Price/Earnings (Normalized)
Price/Sales
121.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
21

Valuation

Metric
ADXS
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
121.53
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ADXS
Quick Ratio
0.20
Current Ratio
0.30
Interest Coverage
−2.30
Quick Ratio
ADXS

Profitability

Metric
ADXS
Return on Assets (Normalized)
−380.79%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ADXS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RnhsprjgtsXsl$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
WnzrznyZrbxf$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
WjdvqdmlVcvjzny$116.0 Bil
Moderna Inc
MRNA
WdjfhtyxsKdvf$51.1 Bil
argenx SE ADR
ARGX
KsfbvmvxGml$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
JnxbwzqfHgdttg$21.0 Bil
BioNTech SE ADR
BNTX
XpmptzqzFrxrg$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
CfbwgvwxKmnzpcs$15.9 Bil
United Therapeutics Corp
UTHR
SlphsmnvrSrkb$14.0 Bil
Incyte Corp
INCY
ZkyspfnkwTvsjtmn$12.5 Bil

Sponsor Center